03/01/2013: ZGNX PDUFA for Zohydro ER got delayed
03/7/2013: THRX FDA advisory committee delayed decision.
03/07/2013: GSK FDA Panel to review BREO ELLIPTA for long term maintenance treatement of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary disease.
03/17/2013: BMY : FDA decision on Eliquis to reduce risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
03/18/2013: BLRX DMC will provide estimate of total number of required for study of phase 2 drug.
03/21/2013: TTNP.OB FDA panel to review probuphine for the maintenance treatment of adult patients with opioid dependence.
03/27/2013: ARIA FDA decision on Ponatinib for patients with resistant or intolerant chronic myeloid leukemia.
03/28/2013: ZIOP Phase 3 data.
03/27/2013: APPA.OB FDA Decision on APF530 for prevention of acute and delayed onset chemotherapy induced nausea and vomiting.
03/30/2013: EXAS Phase 3 data for DeeP-C pivotal trial of Cologuard for colorectal cancer.
03/31/2013: UTHR FDA decision on oral Treprostinil for treatment of pulmonary arterial hypertension.
03/31/2013: JNJ FDA decision on INVOKANA for treatment of type 2 diabetes in adult patients.
03/31/2013: AEZS NDA filing for AGHD.
03/31/2013: AUXL Phase 2a data of XIAFLEX.
03/31/2013: DRRX NDA filing for POSIDUR
03/31/2013: IGXT NDA filing of RIZAtriptan.
03/31/2013: INO Phase 2 data of DNA vaccine.
03/31/2013: INSV Phase 3 data of Bromsite
03/31/2013: PTIE Resubmission of Remoxy
03/31/2013: CYCC Phase 3 data for Sapacitabine.
03/31/2013: ALIM NDA resubmission of Illuvien for Diabetic
03/31/2013: ANAC Phase 2 data for AN2728 in atopic dermatitits.
